Tacrolimus ointment: a selective T-cell immunosuppressant in dermatology

Tacrolimus ointment is a topical calcineurin inhibitor with potent anti-inflammatory activity that suppresses T-cell activation and the production of pro-inflammatory cytokines. Unlike topical glucocorticosteroids, the drug does not cause skin atrophy and epidermal thinning, making it particularly valuable for long-term use in steroid-sensitive areas — such as the face, skin folds, and the anogenital region. In addition to its primary anti-inflammatory effect, tacrolimus ointment possesses clinically significant antipruritic property and fungistatic activity against Malassezia spp., which expands the spectrum of its therapeutic potential. Atopic dermatitis remains the only officially registered indication; however, over the past 20 years, independent researchers have amassed an extensive evidence base covering more than 50 conditions — ranging from vitiligo, lichen planus, and cutaneous lupus erythematosus to lichen sclerosus et atrophicus, rosacea, seborrheic dermatitis, and psoriasis in sensitive areas. For a number of them, the evidence base includes randomized controlled trials and meta-analyses. The drug has been included in domestic and international clinical guidelines for more than 20 disease entities. This publication presents a systematic analysis of the pharmacodynamic profile of tacrolimus ointment and the rationale for its use beyond atopic dermatitis. A total of 6 clinical cases from the practice of dermatovenereologists across various regions of Russia are presented as illustrations: discoid lupus erythematosus, rosacea, seborrheic dermatitis, allergic contact dermatitis of the face, seborrheic psoriasis, and prurigo nodularis. In all cases, the use of tacrolimus ointment resulted in pronounced clinical improvement and was well tolerated, including in patients with prior steroid dependence or in anatomical areas where long-term use of topical glucocorticosteroids is undesirable.